NASDAQ: ARWR
ARROWHEAD PHARMACEUTICALS, INC.CIK 0000879407 · SIC 2834 · Pharmaceutical Preparations
Mid
Revenue $829M
Assets $2.1B
as of Oct 27, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (WCN 10-Q) is open in full — no account needed.
8-K
Filed Aug 4, 2026
· Period ending Aug 4, 2026
Summary not yet generated.
10-Q
Filed Aug 4, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
Partner
Trade ARWR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Jun 16, 2026
· Period ending Jun 12, 2026
Summary not yet generated.
10-Q
Filed May 7, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
8-K
Filed May 7, 2026
· Period ending May 7, 2026
Summary not yet generated.
424B5
Filed Jan 9, 2026
Summary not yet generated.
424B5
Filed Jan 9, 2026
Summary not yet generated.
424B5
Filed Jan 7, 2026
Summary not yet generated.
10-K
Filed Nov 25, 2025
· Period ending Sep 30, 2025
Summary not yet generated.
10-K/A
Filed Oct 10, 2025
· Period ending Sep 30, 2024
Summary not yet generated.
10-K
Filed Nov 26, 2024
· Period ending Sep 30, 2024
Summary not yet generated.
424B3
Filed Sep 29, 2016
Summary not yet generated.
424B3
Filed Feb 13, 2014
Summary not yet generated.
424B3
Filed Nov 6, 2013
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 4, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations (Unaudited)
(in thousands, except per share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Nine months ended June 30, 2026 | Nine months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | 75,253 | 27,767 | 413,023 | 572,976 |
| Operating expenses: | ||||
| Research and development | 198,223 | 162,368 | 548,679 | 432,472 |
| Selling, general and administrative | 47,123 | 30,949 | 134,888 | 86,264 |
| Total operating expenses | 245,346 | 193,317 | 683,567 | 518,736 |
| Operating (loss) income | (170,093) | (165,550) | (270,544) | 54,240 |
| Other income (expense): | ||||
| Interest income | 16,935 | 11,019 | 43,496 | 28,236 |
| Interest expense | (24,562) | (24,382) | (70,913) | (67,667) |
| Loss on equity method investment | (2,470) | — | (9,190) | — |
| Gain on VIE's sale of IPR&D assets | — | — | 19,000 | — |
| Other, net | 1,285 | (176) | (52) | 603 |
| Total other (expense) income | (8,812) | (13,539) | (17,659) | (38,828) |
| (Loss) income before income tax expense (benefit) and noncontrolling interest | (178,905) | (179,089) | (288,203) | 15,412 |
| Income tax expense (benefit) | 11 | (437) | 46 | 1,419 |
| Net (loss) income including noncontrolling interest | (178,916) | (178,652) | (288,249) | 13,993 |
| Net income (loss) attributable to noncontrolling interest, net of tax | 15,364 | (3,411) | 7,956 | (8,126) |
| Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. | (194,280) | (175,241) | (296,205) | 22,119 |
| Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.: | ||||
| Basic | (1.36) | (1.26) | (2.10) | 0.17 |
| Diluted | (1.36) | (1.26) | (2.10) | 0.17 |
| Weighted-average shares used in calculating | ||||
| Basic | 143,378 | 139,039 | 141,331 | 132,385 |
| Diluted | 143,378 | 139,039 | 141,331 | 133,352 |
| Comprehensive (loss) income: | ||||
| Net (loss) income including noncontrolling interest | (178,916) | (178,652) | (288,249) | 13,993 |
| Other comprehensive (loss) income, net of tax: | ||||
| Unrealized gains (losses) on available-for-sale securities, net | (2,254) | 876 | (9,042) | 1,022 |
| Foreign currency translation adjustments | 487 | 91 | 1,588 | (415) |
| Total other comprehensive income (loss) | (1,767) | 967 | (7,454) | 607 |
| Comprehensive (loss) income | (180,683) | (177,685) | (295,703) | 14,600 |
| Comprehensive income (loss) attributable to noncontrolling interest | 15,573 | (3,411) | 8,609 | (8,126) |
| Comprehensive (loss) income attributable to Arrowhead Pharmaceuticals, Inc. | (196,256) | (174,274) | (304,312) | 22,726 |
Consolidated Balance Sheets
(in thousands, except per share amounts)
| Description | June 30, 2026 (unaudited) | September 30, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash, cash equivalents and restricted cash | 19,685 | 88,706 |
| Cash at variable interest entity | 35,074 | 137,842 |
| Accounts receivable | 8,556 | 6,824 |
| Available-for-sale securities, at fair value | 1,547,201 | 692,818 |
| Prepaid expenses | 25,373 | 10,933 |
| Other current assets | 35,522 | 13,516 |
| Total current assets | 1,671,411 | 950,639 |
| Property, plant and equipment, net | 373,301 | 382,515 |
| Intangible assets, net | 5,586 | 6,861 |
| Right-of-use assets | 55,667 | 43,891 |
| Other assets | 6,048 | 1,389 |
| Total Assets | 2,112,013 | 1,385,295 |
| LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 27,776 | 17,674 |
| Accrued expenses | 86,174 | 90,419 |
| Accrued payroll and benefits | 23,455 | 26,895 |
| Lease liabilities | 5,322 | 7,289 |
| Deferred revenue | 94,596 | 2,399 |
| Credit facility | 40,000 | 40,000 |
| Other liabilities | 6,023 | 10,811 |
| Total current liabilities | 283,346 | 195,487 |
| Long-term liabilities: | ||
| Lease liabilities, net of current portion | 114,298 | 104,112 |
| Deferred revenue, net of current portion | 31,743 | — |
| Liability related to the sale of future royalties | 392,512 | 367,397 |
| Credit facility, net of current portion | 141,366 | 214,883 |
| Convertible Notes, Net | 682,707 | — |
| Total long-term liabilities | 1,362,626 | 686,392 |
| Commitments and contingencies (Note 7) | ||
| Noncontrolling interest and stockholders’ equity: | ||
| Common stock, $0.001 par value: Authorized 290,000 shares; 143,796 shares issued and 141,135 outstanding as of June 30, 2026 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025 | 237 | 231 |
| Additional paid-in capital | 2,443,074 | 2,139,725 |
| Accumulated other comprehensive (loss) income | (1,234) | 6,443 |
| Accumulated deficit | (1,923,355) | (1,627,154) |
| Treasury stock; at cost; 2,661 shares of common stock at June 30, 2026 and September 30, 2025 | (53,193) | (53,193) |
| Stockholders’ equity | 465,529 | 466,052 |
| Noncontrolling interest | 512 | 37,364 |
| Total noncontrolling interest and stockholders’ equity | 466,041 | 503,416 |
| Total Liabilities, Noncontrolling Interest and Stockholders’ Equity | 2,112,013 | 1,385,295 |
Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Description | Nine months ended June 30, 2026 | Nine months ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net (loss) income | (288,249) | 13,993 |
| Adjustments to reconcile net (loss) income to net cash flow from operating activities | ||
| Stock-based compensation | 50,913 | 44,279 |
| Depreciation and amortization | 19,417 | 17,542 |
| Accretion of available-for-sale securities premiums/discounts | (4,122) | (4,545) |
| Amortization of convertible notes issuance costs | 1,423 | — |
| Realized gain on investments | (36) | — |
| Non-cash interest expense on liability related to the sale of future royalties | 25,115 | 18,893 |
| Non-cash interest expense on credit facility | 44,374 | 48,774 |
| Loss on equity method investment | 9,190 | — |
| Gain on VIE's sale of IPR&D assets | (19,000) | — |
| Non-cash transfer of property and equipment to affiliate | 579 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,907) | (9,841) |
| Prepaid expenses and other current assets | (29,940) | (22,342) |
| Accounts payable | 9,980 | 21,662 |
| Accrued expenses | (15,214) | 7,956 |
| Deferred revenue | 123,940 | 22,979 |
| Operating lease, net | (3,556) | (3,417) |
| Other | (2,453) | 3,128 |
| Net cash (used in) provided by operating activities | (79,546) | 159,061 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property, plant and equipment | (8,567) | (15,177) |
| Purchases of available-for-sale securities | (1,138,714) | (774,616) |
| Proceeds from sales of available-for-sale securities | 48,788 | — |
| Proceeds from maturities of available-for-sale securities | 224,152 | 587,880 |
| Net cash used in investing activities | (874,341) | (201,913) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from the exercises of stock options | 12,763 | 3,476 |
| Proceeds from issuance of warrants | 99,998 | 25,000 |
| Proceeds from issuance of convertible notes | 700,000 | — |
| Payments of debt issuance costs | (18,716) | (5,000) |
| Purchase of capped calls | (47,880) | — |
| Proceeds from issuance of common stock related to ATM offering | 76,109 | 241,388 |
| Payments of issuance costs of common stock related to ATM offering | (2,038) | — |
| Proceeds from issuance of common stock related to follow-on offering | 130,000 | — |
| Payments of issuance costs of common stock related to follow-on offering | (13,393) | — |
| Repayments of credit facility | (117,891) | (201,625) |
| Proceeds from Visirna credit agreement | — | 7,098 |
| Dividends paid by variable interest entity to noncontrolling shareholders | (38,434) | — |
| Net cash provided by financing activities | 780,518 | 70,337 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (173,369) | 27,485 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | 1,580 | (377) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||
| BEGINNING OF PERIOD | 226,548 | 102,685 |
| END OF PERIOD | 54,759 | 129,793 |
| Supplemental disclosure of cash flows: | ||
| Interest paid | — | (19) |
| Income taxes paid | (21,587) | (81) |
| Supplemental disclosure of non-cash investing activities: | ||
| Capital expenditures included in accrued expenses | 1,084 | 346 |
| Supplemental disclosure of non-cash financing activities: | ||
| ROU assets obtained in exchange for new lease liabilities | 13,410 | — |
Amounts as printed on the EDGAR/iXBRL face — (in thousands, except per share amounts); (in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗